Seres Therapeutics (MCRB) announced that it has formed a new collaboration with privately held Emulate. According to the terms of the agreement, Seres and Emulate will work to further advance Emulate�s Intestine-Chip platform, a micro-engineered, living-tissue-based system that models the human intestine. Seres intends to use the technology to identify novel bacteria compositions with therapeutic potential. The company expects Emulate�s technology platform will enhance its approach for drug discovery and accelerate its efforts to identify promising new microbiome therapeutic candidates for inflammatory bowel disease, other autoimmune or immunological conditions, infectious diseases, and other serious disease states, which may have a microbiome therapeutic based solution.